Cosmegen Related Published Studies
Well-designed clinical trials related to Cosmegen (Dactinomycin)
Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. [2005.04]
Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. [1998.10.01]
Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. [1998.01]
A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor. Results after extended follow-up. Brazilian Wilms' Tumor Study Group. [1994.06.15]
Single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor. Preliminary results of a clinical trial. The Brazilian Wilms' Tumor Study Group. [1991.06.15]
Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. [1990.09]
A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. [1989.03]
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. [1988.08]
Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. [1988.04]
Well-designed clinical trials possibly related to Cosmegen (Dactinomycin)
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. [2008.09.20]
Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. [2006.10]
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. [2006.08.20]
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. [2005.04.20]
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. [2004.10.06]
Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. [2004.10.02]
Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. [2004.09.01]
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. [2004.07.15]
Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. [2004.02.01]
Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. [2003.04.15]
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. [2003.02.20]
Perspectives of drug-eluting stents: the next revolution. [2002]
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. [2001.11]
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. [2001.06.15]
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. [2001.05]
Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. [2001.03.15]
Prophylactic actinomycin D for high-risk complete hydatidiform mole. [2001.02]
Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. [2001.01.15]
Systemic therapy for treating locoregional recurrence in women with breast cancer. [2001]
Bleomycin, actinomycin-D, and cisplatin treatment of ovarian germ-cell malignancies contributes to reducing adverse drug reactions. [2000.11]
Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. [2000.06]
Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. [2000.06]
Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. [1999.06.01]
Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. [1999.04]
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. [1999.01]
Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. [1998.12.01]
Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. [1998.12]
A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. [1998.08.01]
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. [1998.07]
Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. [1998.06]
Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. [1998.04]
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. [1997.09.27]
Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. [1996.03]
Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. [1995.09]
Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. [1995.07.15]
The Third Intergroup Rhabdomyosarcoma Study. [1995.03]
Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group. [1995]
Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. [1994.10]
The relationship between microsubstaging variables, age at diagnosis, and tumor weight of children with stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor study. [1994.09.15]
The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms' tumor. A report from the National Wilms' Tumor Study. [1994.08]
Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. [1993.06]
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. [1993.04]
The Intergroup Rhabdomyosarcoma Study-II. [1993.03.01]
Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study. [1993.01]
Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. [1993]
[Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO therapy study] [1992.07]
Results of two radiation therapy randomizations in the third National Wilms' Tumor Study. [1991.10.15]
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. [1991.08]
[A randomized trial of PVB, VAB-6, BVP regimen versus PEB chemotherapy in patients with disseminated testicular tumors] [1991.06]
Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: a report of the Intergroup Rhabdomyosarcoma Study. [1991.05]
Levamisole in the treatment of advanced breast cancer. A ten-year follow-up of a randomized study. [1991]
Treatment of testicular cancer: a new and improved model. [1990.11]
Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. [1990.10]
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. [1990.09.01]
Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. [1990.09]
Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. [1990]
[Alternative chemotherapy of malignant bone neoplasms in children] [1990]
[Prevention of stomatitis induced by anti-cancer drugs] [1989.10]
Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. [1989.07.15]
How to establish equivalence between treatments: a one-sided clinical trial in paediatric oncology. [1989.05]
A randomised controlled trial of adjuvant hormono-chemotherapy in Stage II breast cancer. [1988.12]
Acute toxicities associated with radiation in the second National Wilms' Tumor Study. [1988.11]
Improvement of long-term survival in extensive small-cell lung cancer. [1988.07]
[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia] [1988.05]
Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. [1988.02]
The Intergroup Rhabdomyosarcoma Study-I. A final report. [1988.01.15]
Cyclic alternating polychemotherapy with or without upper and lower half-body irradiation in small cell anaplastic lung cancer. A randomized study. [1987.02]
Other research related to Cosmegen (Dactinomycin)
Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor. [2008.09]
Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. [2008.01]
Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. [2006.09.15]
Dactinomycin-induced, severe lichenoid eruption in a child. [2006.09]
A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. [2006.08]
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. [2005.08.15]
Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. [2004.11]
Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. [2004.07]
Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. [2004.05.15]
Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope. [2004.02]
[The effect of dactinomycin on retinal injury induced by argon laser in mouse] [2000.07]
Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. [2000.05]
Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. [1999.12]
Cutaneous toxicity following the administration of dactinomycin. [1997.09]
Ultrasound in the management of hepatic veno-occlusive disease in three children treated with dactinomycin and vincristine. [1996.11]
[Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)] [1995.11]
Complete response of a persistent ectopic pregnancy to dactinomycin after methotrexate failure. A case report. [1995.02]
Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and 5-fluorouracil chemotherapy protocol. [1994.05]
Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. [1994.01]
Severe acne and hyperandrogenemia following dactinomycin. [1993]
Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncolysis. [1991.05.15]
Dactinomycin potentiation of radiation pneumonitis: a forgotten interaction. [1991.04]
Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. [1991.02]
Other possibly related research studies
Long-term effects of chemotherapy on dental status in children treated for nephroblastoma. [2005.10]
Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group. [2005.10]
|
